Pharmaceutical Intermediates Market Future Business Scope, Trends and Forecast to 2028 – Pfizer Inc; Sanofi, ; BASF SE, ; Lianhe Chemical Technology Co

Pharmaceutical Intermediates Market

The pharmaceutical intermediates market is expected to reach US$ 37,290.33 million in 2028 from US$ 27,356.70 million in 2020. The market is estimated to grow with a CAGR of 4.2% from 2021-2028.

The pharmaceutical intermediates market has been analyzed on the basis of type, application, distribution channel, and region. The market based on region is segmented into North America, Europe, Asia Pacific, the Middle East and Africa, and South and Central America. The report emphasizes on parameters such as market trends, technological advancements, market dynamics, and leading company’s competitive landscape analysis to offers insights and in-depth analysis of the pharmaceutical intermediates market. It also includes the analysis of COVID-19 pandemic across the market in all the key regions.

Download sample Report Copy @

Top Market Player

Pfizer Inc; Sanofi, ; BASF SE, ; Lianhe Chemical Technology Co., Ltd, ; Dishman Carbogen Amcis Ltd, ; Codexis, ; Midas Pharma GmbH, ; chiracon GmbH, ; Dextra Laboratories Limited, ; and Vertellus Holdings LLC are among the leading companies operating in the pharmaceutical intermediate market.

Pharmaceutical intermediates are the building blocks of active pharmaceutical ingredients (APIs). These are raw materials that undergo molecular change or processing during bulk drug production. Thus, the requirement of pharmaceutical intermediates increases with the rise in demand for drugs to treat chronic diseases. As per the Centers for Disease Control and Prevention (CDC), 6 in 10 adults in the US suffer from at least one chronic disease such as cancer, heart disease, lung disease, stroke, neurological disease, diabetes, and kidney diseases. Moreover, 4 in 10 adults in the country have two or more chronic diseases. Additionally, according to the press release by the European Chronic Disease Alliance (ECDA), in 2014, 9 out of 10 people in Europe die due to chronic diseases. Thus, 70–80% of the total healthcare costs are spent on the management of chronic diseases.

The surging prevalence of infectious diseases, especially in Southeast Asia, is also likely to propel the demand for APIs in the coming years, eventually driving the growth of the pharmaceutical intermediate market. For instance, as per the Revised National Tuberculosis Control Programme Report, around 4.4 lakh patients died due to tuberculosis in India in 2018, that is 29% of the total 1.5 million deaths caused by the disease across the world. Thus, such high prevalence of chronic diseases and infectious diseases is bolstering the demand for drugs, eventually highlighting the need of pharmaceutical intermediates.

The report segments global Pharmaceutical Intermediate market as follows:

By Type

  • GMP
  • Non GMP

By Application

  • Antibiotics
  • Antipyretic analgesics
  • Vitamins
  • Others

By Distribution Channel

  • Distributor
  • Direct Sales

By Geography

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • UK
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific (APAC)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of APAC
  • Middle East & Africa (MEA)
    • Saudi Arabia
    • UAE
    • South Africa
    • Rest of MEA
  • South and Central America (SCAM)
    • Brazil
    • Argentina
    • Rest of SCAM

Purchase Full Copy of This Report @

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defence.

Contact Us:

Call: +1-646-491-9876


Related Articles

Back to top button